Company intelligence / Profile preview
Daval International Ltd
London, England, United Kingdomorpha.net ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Phase 2
01
Overview
Daval International developed AIMSPRO, a goat serum-derived polyclonal antibody therapy, which reached Phase 2 clinical trials for secondary progressive multiple sclerosis and systemic sclerosis. The company sponsored at least two Phase 2 studies, but the current status of these programs is unknown due to the company's dissolution in January 2023. No recent clinical results are available.[1][5]
- Therapeutic areas
- NeurologyRheumatology
- Modalities
- Polyclonal antibodies (goat serum-derived)[5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly listed.
Beyond the preview
Go deeper on Daval International Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Daval International Ltd.